Back to results
US 5,571,801 AGranted
Plasma expander and blood substitute
AssigneeBioTime, Inc.
InventorsPaul E. Segall, Harold D. Waitz, Hal Sternberg, Judith M. Segall
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeBioTime, Inc.
InventorsPaul E. Segall, Harold D. Waitz, Hal Sternberg, Judith M. Segall
Estimating the term…
An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a pre-administration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed. The use of the plasma-like solution in organ transplant, novel chemotherapy procedures, and tissue, organ and organism cryopreservation are also disclosed.
A blood-free plasma expander and blood substitute for use in a subject in need thereof, comprising a single solution with at least two water soluble oncotic agents, one of which is a water soluble polysaccharide oncotic agent and one of which is serum albumin, wherein said polysaccharide is selected from the group consisting of dextran 70 and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent.
A blood-free plasma expander and blood substitute for use in a subject in need thereof comprising a single solution with at least two water soluble oncotic agents, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent, and wherein one of said oncotic agents is a water soluble polysaccharide selected from the group consisting of dextran 70 and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, and one of which is serum albumin, wherein the ratio of the weight of said water soluble polysaccharide to said serum albumin is between 1:1 and 1:2, and further comprising cations in the following concentrations:
A blood-free plasma expander and blood substitute for use in a subject in need thereof, comprising a single solution with at least two water soluble polysaccharide oncotic agents selected from the group consisting of dextran 40, dextran 70, hydroxyethyl starch having an average molecular weight of 350,000 daltons or lower, and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent, and further comprising at least one cold protecting agent.
A blood-free plasma expander and blood substitute for use in a subject in need thereof, comprising a single solution with at least two water soluble polysaccharide oncotic agents selected from the group consisting of dextran 40, dextran 70, hydroxyethyl starch having an average molecular weight of 350,000 daltons or lower, and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent.
Dependencies are inferred from the claim text.